Search company, investor...

Stage

Acquired | Acquired

Total Raised

$18M

About NeuroLogica

NeuroLogica specializes in the design and manufacture of imaging equipment that is easy to use and brings the power of imaging to the patient. NeuroLogica's BodyTom CT and CereTom CT are FDA registered and the quality system is certified to ISO 13485:2003 and ISO 9001:2008 with Canadian Medical Device Amendments. In January 2013, NeuroLogica was acquired by Samsung. The valuation of NeuroLogica was undisclosed. Other terms of the deal were not released.

Headquarters Location

14 Electronics Ave

Danvers, Massachusetts, 01923,

United States

978-564-8500

Loading...

Loading...

NeuroLogica Patents

NeuroLogica has filed 37 patents.

The 3 most popular patent topics include:

  • medical imaging
  • medical physics
  • imaging
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/12/2022

1/30/2024

Stroke, Medical imaging, Vascular diseases, Cerebrovascular diseases, Medical physics

Grant

Application Date

4/12/2022

Grant Date

1/30/2024

Title

Related Topics

Stroke, Medical imaging, Vascular diseases, Cerebrovascular diseases, Medical physics

Status

Grant

Latest NeuroLogica News

NeuroLogica announces additional FDA clearance for CT scanner

Jul 22, 2024

닫기 NeuroLogica Corp., a U.S. subsidiary of Samsung Electronics, received additional U.S. FDA clearance on July 10 for  new features of OmniTom Elite Photon Counting Detector (PCD), an advanced CT scanner. The new features include an ultra-high resolution mode, PCD-specific applications, expanded scanning range, and continuous helical scanning capabilities. NeuroLogica Corp., a subsidiary of Samsung Electronics, received additional FDA clearance for the OmniTom Elite Photon Counting Detector (PCD) on July 10, introducing new features such as an ultra-high resolution mode, PCD-specific applications, expanded scanning range, and continuous helical scanning capabilities. The OmniTom Elite's PCD technology is a next-generation CT scanning advancement that uses semiconductors to deliver higher resolution and lower electronic noise in CT images compared to conventional scintillator-based methods. Samsung Medison, a Korean medical device maker uner Samsung Electronics, said that the FDA-cleared upgrade to the OmniTom Elite PCD introduces an ultra-high resolution mode for superior image quality. The imaging can also be adjusted to remove residual contrast seen in CT scans taken after contrast has been administered. The OmniTom Elite PCD was the world's first mobile CT with PCD technology to receive FDA clearance in 2022. “With these new features, the OmniTom Elite PCD is poised to be even more competitive in the global mobile CT market,” Samsung Medison said. “We are pleased to receive additional FDA clearance for the development of new features to improve diagnostic convenience,” said Yoo Kyu-tae, GM of Samsung Electronics HME Business and CEO of Samsung Medison. “We will continue to lead the development of new technologies in the medical imaging field to improve diagnostic accuracy while providing convenience to medical staff. In Korea, the Ministry of Food and Drug Safety approved OmniTom Elite PCD last year, following its existing FDA approval. Meanwhile, the OmniTom Elite PCD is pending to receive CE MDR (European Union Medical Device Regulation) certification for its new FDA-approved features.

NeuroLogica Frequently Asked Questions (FAQ)

  • Where is NeuroLogica's headquarters?

    NeuroLogica's headquarters is located at 14 Electronics Ave, Danvers.

  • What is NeuroLogica's latest funding round?

    NeuroLogica's latest funding round is Acquired.

  • How much did NeuroLogica raise?

    NeuroLogica raised a total of $18M.

  • Who are the investors of NeuroLogica?

    Investors of NeuroLogica include Samsung Electronics and Stata Venture Partners.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.